AXL-TBK1 driven AKT3 activation promotes metastasis
Sci Signal. 2024 Dec 17;17(867):eado6057. doi: 10.1126/scisignal.ado6057. Epub 2024 Dec 17.
Published on December 17, 2024
ABSTRACT
The receptor tyrosine kinase AXL promotes tumor progression, metastasis, and therapy resistance through the induction of epithelial-mesenchymal transition (EMT). Here, we found that activation of AXL resulted in the phosphorylation of TANK-binding kinase 1 (TBK1) and the downstream activation of AKT3 and Snail, a transcription factor critical for EMT. Mechanistically, we showed that TBK1 directly bound to and phosphorylated AKT3 in a manner dependent on the multiprotein complex mTORC1. Upon activation, AKT3 interacted with and promoted the nuclear accumulation of Snail, which led to increased EMT as assessed by marker abundance. In human pancreatic ductal adenocarcinoma tissue, nuclear AKT3 colocalized with Snail and correlated with worse clinical outcomes. Primary mouse pancreatic cancer cells deficient in AKT3 showed reduced metastatic spread in vivo, suggesting selective AKT3 inhibition as a potential therapeutic avenue for targeting EMT in aggressive cancers.
PMID:39689180 | DOI:10.1126/scisignal.ado6057
Latest Publications
- Testosterone Exposure During Fetal Masculinization Programming Window Determines the Kidney Size in Adult Mice
- Genomic history of early dogs in Europe
- miR-199a-3p Promotes Adipogenic Differentiation to Aggravate Steroid-Induced Osteonecrosis of Femoral Head via the ITGB8/FAK-ERK/RUNX2 Pathway
- Macrophages restrict tumor immune infiltration by controlling collagen topography
- Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5′-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors